Catalyst
Slingshot members are tracking this event:
Alder (ALDR) Plans to Announce Top-Line Data From 24 Week Phase 2b Study of ALD-403 in Chronic Migraine Patients By Mid-Year 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALDR |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 15, 2016
Occurred Source:
http://investor.alderbio.com/releasedetail.cfm?ReleaseID=989218
Related Projects
Related Keywords
Phase 2b Follow-on Study, Optimal Dosing For Efficacy, 12-week Period, Frequent Episodic Migraine Patients, Ald403
